Lillys Mounjaro, whose main ingredient is tirzepatide, was approved by the FDA in 2022 to treat diabetes, though it has also been used for weight loss
In individuals without established CVD but with multiple cardiovascular risk factors (such as age 55 years, obesity, hypertension, smoking, dyslipidaemia or albuminuria), a GLP-1 RA with proven benefit could be used to reduce MACE, or an SGLT2i with proven benefit could be used to reduce MACE and HF and improve kidney outcomes
The main concern is fat-soluble vitamins (A, D, E, and K), which need dietary fat for absorption
You should check your levels more frequently than before, especially before meals and at bedtime
It is best to choose a spot like your upper arm or your abdomen for the injection
Failure to Warn Allegations Lawsuits against Novo Nordisk and Eli Lilly are built on allegations that both pharmaceutical companies failed to properly warn consumers about the health risks tied to their GLP-1 drugs